Review of the Canadian Diabetes Risk Assessment Questionnaire (CANRISK)
Evidence to Action: Official Journal of MDCalc · 26.06.2026 · 022026 (01)
DOI: 10.65357/001c.163855 ↗Kurz gefasst
Fachartikel in der Zeitschrift Evidence to Action: Official Journal of MDCalc, online erschienen am 26.06.2026. Verfasst von Michelle D. Lundholm. Die Arbeit nennt 16 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The CANRISK score is a validated clinical tool for estimating the risk of prediabetes and undiagnosed type 2 diabetes in Canadian adults. It can be used to guide screening decisions but is not diagnostic. High and very high scores warrant HbA1c or other diagnostic testing for diabetes every 3-5 years or annually, respectively. The tool was developed and validated in Canadian cohorts, including multi-ethnic populations, and performs comparably to FINDRISC. Clinicians should apply judgment for high-risk features that are not captured by the CANRISK calculator.
Zitieren
APA
Lundholm, M. D. (2026). Review of the Canadian Diabetes Risk Assessment Questionnaire (CANRISK). Evidence to Action: Official Journal of MDCalc, 022026(01). https://doi.org/10.65357/001c.163855
Vancouver
Lundholm MD. Review of the Canadian Diabetes Risk Assessment Questionnaire (CANRISK). Evidence to Action: Official Journal of MDCalc. 2026;022026(01). doi:10.65357/001c.163855
BibTeX
@article{Lundholm2026,
author = {Lundholm, Michelle D.},
title = {Review of the Canadian Diabetes Risk Assessment Questionnaire (CANRISK)},
journal = {Evidence to Action: Official Journal of MDCalc},
year = {2026},
volume = {022026},
number = {01},
doi = {10.65357/001c.163855}
}
EUVIMED